KYTX Stock Summary and Trading Ideas (Kyverna Therapeutics | NASDAQ:KYTX)

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.

As of April 10, 2026, KYTX stock price declined to $8.95 with 645,478 million shares trading.

KYTX has a beta of 1.71, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.07 to the broad based SPY ETF.

KYTX has a market cap of $541.07 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IBB, VXF, SCHA, DWAS.

KYTX has outperformed the market in the last year with a price return of +378.6% while the SPY ETF gained +30.9%. KYTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.6% and +14.7%, respectively, while the SPY returned -1.8% and +7.2%, respectively.

KYTX support price is $9.10 and resistance is $10.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.